Literature DB >> 7060005

Enterohepatic circulation of methotrexate in rats in vivo.

S E Steinberg, C L Campbell, W A Bleyer, R S Hillman.   

Abstract

The pharmacokinetics of the methotrexate enterohepatic cycle were studied in rats in vivo. For plasma levels of methotrexate between 10(-5) and 10(-8) M, biliary levels were directly proportional and concentrated 27-fold. When labeled methotrexate was administered in doses sufficient to achieve plasma levels of 10(-6) M, approximately 50% of methotrexate appeared in the bile in normal animals and up to 80% appeared in anephric animals. In spite of the high percentage of administered methotrexate which appeared in the bile, complete interruption of the enterohepatic cycle in otherwise normal animals did not affect the plasma decay curve of a bolus of methotrexate. The increased biliary excretion which occurred in animals with renal impairment was utilized with possible therapeutic implications. Bile drainage in these animals rapidly decreased plasma methotrexate levels compared to nondrained controls. This suggests that interruption of the methotrexate enterohepatic cycle may provide an alternative for the management of methotrexate toxicity associated with renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7060005

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.

Authors:  Michele Visentin; Ersin Selcuk Unal; Rongbao Zhao; I David Goldman
Journal:  Cancer Chemother Pharmacol       Date:  2013-07-24       Impact factor: 3.333

2.  Tissue localization of methotrexate-monoclonal-IgM immunoconjugates: anti-SSEA-1 and MOPC 104E in mouse teratocarcinomas and normal tissues.

Authors:  B Ballou; R Jaffe; S Persiani; W C Shen; J J Langone; H Sands; J M Reilandu; J Curley; T R Hakala
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate.

Authors:  Sayaka Kato; Katsuaki Ito; Yukio Kato; Tomohiko Wakayama; Yoshiyuki Kubo; Shoichi Iseki; Akira Tsuji
Journal:  Pharm Res       Date:  2009-03-14       Impact factor: 4.200

4.  Inhibitory effect of bile salts on the enterohepatic circulation of methotrexate in the unanesthetized rat: inhibition of methotrexate intestinal absorption.

Authors:  H M Said; D Hollander
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats.

Authors:  D I Jodrell; D R Newell; W Gibson; L R Hughes; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Inhibition of 7-hydroxymethotrexate formation by amsacrine.

Authors:  R M Bremnes; E Smeland; N P Willassen; E Wist; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation.

Authors:  Renuka R Nayak; Margaret Alexander; Ishani Deshpande; Kye Stapleton-Gray; Bipin Rimal; Andrew D Patterson; Carles Ubeda; Jose U Scher; Peter J Turnbaugh
Journal:  Cell Host Microbe       Date:  2021-01-12       Impact factor: 21.023

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.